CT26.CL25 (ATCC® CRL-2639)

Organism: Mus musculus, mouse  /  Disease: Carcinoma,Leukemia

Organism Mus musculus, mouse
Product Format frozen
Morphology fibroblast
Culture Properties adherent
Biosafety Level 2 Cells contain SV40 viral DNA sequences
Disease Carcinoma,Leukemia
Strain BALB/c
Applications
The cell line can be used as a model for testing immunotherapy protocols and in studies on the host immune response.
Storage Conditions liquid nitrogen vapor temperature
Derivation
CT26 is an N-nitroso-N-methylurethane-(NNMU) induced, undifferentiated colon carcinoma cell line. It was cloned to generate the cell line designated CT26.WT (ATCC CRL-2638).
CT26.WT was stably transduced with the retroviral vector LXSN that contains the lacZ gene encoding the model tumor associated antigen (TAA), beta-galactosidase (beta-gal).
The cells were grown in G418 for seven days, cloned, and evaluated for beta-gal production.
The lethal subclone CT26.CL25 (ATCC CRL-2639) was selected for use in all in vitro and in vivo studies because of its stable high expression of both beta-gal and the class I molecule H-2 Ld.
Clinical Data
The cell line can be used as a model for testing immunotherapy protocols and in studies on the host immune response.
Antigen Expression
H-2d
Genes Expressed
beta galactosidase (beta-gal),H-2d,The lethal subclone CT26.CL25 (ATCC CRL-2639) was selected for use in all in vitro and in vivo studies because of its stable high expression of both beta-gal and the class I molecule H-2 Ld.
The cell line can be used with CT26.CL25 (ATCC CRL-2639) as a model for testing immunotherapy protocols and in studies on the host immune response.
Tumorigenic Yes
Effects
Yes, in BALB/c mice. Mice inoculated, subcutaneously, developed lethal tumors at 80% frequency with 10 exp3 cells and at 100% with 10 exp4 cells. Pulmonary metastases developed when mice were inoculated, intravenously, with 10 exp4 cells.
Comments
CT26 is an N-nitroso-N-methylurethane-(NNMU) induced, undifferentiated colon carcinoma cell line. It was cloned to generate the cell line designated CT26.WT (ATCC CRL-2638).
CT26.WT was stably transduced with the retroviral vector LXSN that contains the lacZ gene encoding the model tumor associated antigen (TAA), beta-galactosidase (beta-gal).
The vector is driven by the Moloney murine leukemia virus (MoMuLV) long terminal repeat (LTR) promoter and contains a gene controlling resistance to neomycin transcribed from the SV40 promoter.
The cells were grown in G418 for seven days, cloned, and evaluated for beta-gal production.
The lethal subclone CT26.CL25 (ATCC CRL-2639) was selected for use in all in vitro and in vivo studies because of its stable high expression of both beta-gal and the class I molecule H-2 Ld.
The growth rate and lethality of CT26.CL25 and CT26.WT is virtually identical despite the expression by CT26.CL25 of the model TAA, beta-galactosidase, in normal mice.
The cell line can be used as a model for testing immunotherapy protocols and in studies on the host immune response.
Complete Growth Medium RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES and 1.0 mM sodium pyruvate and supplemented with 0.1 mM non-essential amino-acids and 0.4 mg/ml G418, 90%; fetal bovine serum, 10%
Subculturing
Protocol: Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks. Subculture at 80% confluence. Cells pile up and do not become completely confluent.
Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:6 is recommended
Medium Renewal: Every 2 to 3 days
Cryopreservation
Freeze medium: Complete growth medium 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor temperature
Culture Conditions
Temperature: 37.0°C
Name of Depositor N Restifo
References

Wang M, et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol. 154: 4685-4692, 1995. PubMed: 7722321

Chen PW, et al. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J. Immunol. 156: 224-231, 1996. PubMed: 8598466

Irvine KR, et al. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J. Immunol. 156: 238-245, 1996. PubMed: 8598468

Carroll MW, et al. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 15: 387-394, 1997. PubMed: 9141209

Basic Documentation
References

Wang M, et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol. 154: 4685-4692, 1995. PubMed: 7722321

Chen PW, et al. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J. Immunol. 156: 224-231, 1996. PubMed: 8598466

Irvine KR, et al. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J. Immunol. 156: 238-245, 1996. PubMed: 8598468

Carroll MW, et al. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 15: 387-394, 1997. PubMed: 9141209